Posted on April 10, 20244/10/24
Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs
Posted on February 26, 20242/26/24
Q&A: Enhanced Protection and Consistency for PRCI in Canada
Posted on February 21, 20242/21/24
The Looming Legacy of Software as a Medical Device (SaMD) Misclassification Under Medical Device Directive (MDD)
Posted on February 14, 20242/14/24
Excel in Market Access Success: Key Considerations for Leveraging Your Evidence
Posted on January 30, 20241/30/24
Empowering Success: EVERSANA’s Value & Evidence Team Guides Clients Through CMS Drug Negotiations Under the Inflation Reduction Act
Posted on January 23, 20241/23/24
CES 2024 Recap – How the Future of Healthcare Will Continue to Be Driven By Innovation & AI
Posted on January 22, 20241/22/24
Uncovering Health Disparities: Exploring Social Determinants of Metastatic Prostate Cancer Survival
Posted on January 22, 20241/22/24
EVERSANA’s High-Quality HEOR Methods Recognized in Published Independent Review
Posted on January 15, 20241/15/24
HemGenix Shines in Collaborative ITC Analysis: EVERSANA and CSL Behring Propel Gene Therapy to the Forefront in Hemophilia B Treatment
Posted on January 9, 20241/9/24